I kliniske forsøg var hyppigheden af malignitet var den samme hos de Kineret behandlede og de placebo behandlede patienter, og den var ikke forskellig fra forekomsten i baggrunds populationen.
In clinical trials, the crude incidence rate of malignancy was the same in the Kineret-treated patients and the placebo-treated patients and did not differ from that in the general population.